Trial Profile
A PhaseⅠ,Open-label, Single-center Study to Evaluate Safety and Pharmacokinetics of Recombinant Anti-Epidermal Growth Factor Receptor (EGFr) Antibody in Patients With Metastatic Colorectal Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Kelun Pharmaceutical
- 14 Jan 2017 New trial record